Utilization of Preventive Therapy in Korean Migraine Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background: Migraine is a common neurological disorder that affects the quality of life and causes several health problems. Preventive migraine treatment can reduce migraine frequency, headache severity, and health care costs. This study aimed to estimate the utilization of migraine preventive therapy and associated factors in eligible patients. Methods: We studied 534 patients with migraine who were eligible for migraine preventive therapy using 2017 National Patient Sample (NPS) data from the Health Insurance Review and Assessment Service (HIRA). We estimated the migraine days by calculating the monthly average number of defined daily dose (DDD) of migraine-specific acute drug. Patients with a monthly average number of DDD of 4 or more were considered as subjects for preventive treatment. Chi-square test and multiple logistic regression analysis were used to determine the association between the preventive therapy and the influencing variables. Results: Less than half of the eligible patients for prophylaxis (n=234, 43.8%) were prescribed preventive therapy. Multiple logistic regression results show that migraine preventive therapy was influenced by age, the type of migraine, and some comorbidities. Patients over the age of 50 tend to receive less prophylactic treatment than under the age of 40. On the other hand, migraine patients with epilepsy or depression were more likely to receive preventive therapy. Sumatriptan was the most preferred medication for acute treatment, and propranolol was the most commonly prescribed drug for prevention. Conclusions: More than half of the patients who were candidates for migraine prophylaxis were not receiving suitable preventive treatment. Positive factors affecting the use of migraine prevention were the presence of comorbidities such as epilepsy and depression.
Abstract
Background: Migraine is a common neurological disorder that affects the quality of life and causes several health problems. Preventive migraine treatment can reduce migraine frequency, headache severity, and health care costs. This study aimed to estimate the utilization of migraine preventive therapy and associated factors in eligible patients. Methods: We studied 534 patients with migraine who were eligible for migraine preventive therapy using 2017 National Patient Sample (NPS) data from the Health Insurance Review and Assessment Service (HIRA). We estimated the migraine days by calculating the monthly average number of defined daily dose (DDD) of migraine-specific acute drug. Patients with a monthly average number of DDD of 4 or more were considered as subjects for preventive treatment. Chi-square test and multiple logistic regression analysis were used to determine the association between the preventive therapy and the influencing variables. Results: Less than half of the eligible patients for prophylaxis (n=234, 43.8%) were prescribed preventive therapy. Multiple logistic regression results show that migraine preventive therapy was influenced by age, the type of migraine, and some comorbidities. Patients over the age of 50 tend to receive less prophylactic treatment than under the age of 40. On the other hand, migraine patients with epilepsy or depression were more likely to receive preventive therapy. Sumatriptan was the most preferred medication for acute treatment, and propranolol was the most commonly prescribed drug for prevention. Conclusions: More than half of the patients who were candidates for migraine prophylaxis were not receiving suitable preventive treatment. Positive factors affecting the use of migraine prevention were the presence of comorbidities such as epilepsy and depression.
참고문헌 (30)
- GBD 2016 Disease and Injury Incidence and Prevalence Collaborators, "Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016", Lancet, 390(10100), pp.1211~1259 (2017)
- Lipton RB, "Migraine prevalence, disease burden, and the need for preventive therapy", Neurology, 68(5), pp.343~349 (2007)
- 김병건, "Prevalence and Impact of Migraine and Tension-Type Headache in Korea", Journal of Clinical Neurology, 8(3), pp.204~211 (2012), 대한신경과학회[DOI]
- Lipton RB, "Episodic and chronic migraine headache: breaking down barriers to optimal treatment and prevention", Headache, 55(Suppl 2), pp.103~122 (2015)
- Headache Classification Committee of the International Headache Society (IHS), "The international classification of headache disorders, 3rd edition", Cephalalgia, 38(1), pp.1~211 (2018)
- Silberstein SD, "Migraine preventive medication reduces resource utilization", Headache, 43(3), pp.171~178 (2003)
- 이광수, "편두통의 진단과 최신치료", 대한의사협회지, 52(5), pp.500~506 (2009), 대한의사협회
- Marmura MJ, "The acute treatment of migraine in adults : The American headache society evidence assessment of migraine pharmacotherapies", Headache, 55(1), pp.3~20 (2015)
- Tfelt-Hansen PC, "Evidence-based guideline update : pharmacologic treatment for episodic migraine prevention in adults : report of the Quality Standards subcommittee of the American Academy of Neurology and the American Headache Society", Neurology, 80(9), pp.869~870 (2013)
- Kim L, "A guide for the utilization of health insurance review and assessment service national patient samples", Epidemiol health, 36, pp.e2014008~ (2014)
- Ford JH, "A realworld analysis of migraine : A cross-sectional study of disease burden and treatment patterns", Headache, 57(10), pp.1532~1544 (2017)
- Vo P, "Real-world healthcare resource utilization related to migraine treatment failure: a panel-based chart review in France, Germany, Italy, and Spain", J Med Econ, 22(9), pp.953~959 (2019)
- Piccinni C, "A real-world study on unmet medical needs in triptan-treated migraine: prevalence, preventive therapies and triptan use modification from a large Italian population along two years", J Headache Pain, 20(1), pp.74~ (2019)
- Devine J, "Effect of daily migraine prevention on health care utilisation in an insured patient population", J Headache Pain, 8(2), pp.105~113 (2007)
- Diamond S, "Patterns of diagnosis and acute and preventive treatment for migraine in the United States : results from the American Migraine Prevalence and Prevention study", Headache, 47(3), pp.355~363 (2007)
- Caetano A, "Underuse of prophylactic treatment among Portuguese patients with primary headache : A retrospective observational study", J Oral Facial Pain Headache, 33(3), pp.331~336 (2019)
- Lipton RB, "Medical consultation for migraine : results from the American Migraine Study", Headache, 38(2), pp.87~96 (1998)
- Steiner T, "The prevalence and disability burden of adult migraine in England and their relationships to age, gender and ethnicity", Cephalalgia, 23(7), pp.519~527 (2003)
- Silberstein SD, "Pharmacological approaches to managing migraine and associated comorbidities--clinical considerations for monotherapy versus polytherapy", Headache, 47(4), pp.585~599 (2007)
- Rahimtoola H, "Incidence and determinants of migraine prophylactic medication in the Netherlands", Eur J Clin Pharmacol, 58(2), pp.149~155 (2002)
- Passmore AP, "Determinants of drug utilization in an elderly population in North and West Belfast", Pharmacoepidemiol Drug Saf, 4(3), pp.147~160 (1995)
- Silberstein SD, "Comprehensive management of headache and depression", Cephalalgia, 18(Suppl 21), pp.50~55 (1998)
- Radat F, "Psychiatric comorbidity is related to headache induced by chronic substance use in migraineurs", Headache, 39(7), pp.477~480 (1999)
- Sheftell FD, "Patterns of use of triptans and reasons for switching them in a tertiary care migraine population", Headache, 44(7), pp.661~668 (2004)
- Worthington I, "Canadian Headache Society Guideline : acute drug therapy for migraine headache", Can J Neurol Sci, 40(5 Suppl 3), pp.S1~S80 (2013)
- Evers S, "EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force", Eur J Neurol, 16(9), pp.968~981 (2009)
- Tepper S, "Guidelines for prescribing prophylactic medications for migraine : A survey among headache specialist physicians in different countries", Headache Care, 1(4), pp.267~272 (2004)
- Steiner TJ, "Aids for management of common headache disorders in primary care", J Headache Pain, 8(Suppl 1), pp.S2~ (2007)
- Kim Y, "BMI and metabolic disorders in South Korean adults : 1998 Korea National Health and Nutrition Survey", Obes Res, 12(3), pp.445~453 (2004)
- D’Amico D, "Migraine preventive therapy : Selection of appropriate patients and general principles of management", Expert Rev Neurother, 6(8), pp.1147~1157 (2006)